Stephen B. Heitner
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dr. Stephen B. Heitner

Cardiology
3181 SW Sam Jackson Park Road, Division Of Cardiology OHSU, 
Portland, OR 
20 Years of Experience
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
3181 SW Sam Jackson Park Road, Division Of Cardiology OHSU, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Heitner is a Cardiologist in Portland, Oregon. Dr. Heitner has been practicing medicine for over 20 years and is rated as an Experienced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Transthyretin Amyloidosis, Pacemaker Implantation, and Heart Bypass Surgery.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Specialties
Cardiology
Licenses
Internal Medicine in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

3181 SW Sam Jackson Park Road, Division Of Cardiology OHSU, Portland, OR 97239

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
Enrollment Status: Completed
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drug: JK07
Study Phase: Phase 1
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Enrollment Status: Completed
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Mavacamten
Study Phase: Phase 2
Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy LIVE-HCM/Lifestyle and Exercise in the Long QT Syndrome LIVE-LQTS
Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy LIVE-HCM/Lifestyle and Exercise in the Long QT Syndrome LIVE-LQTS
Enrollment Status: Completed
Publish Date: September 05, 2023
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Withdrawn
Publish Date: May 31, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Enrollment Status: Completed
Publish Date: October 04, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Enrollment Status: Terminated
Publish Date: August 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

97 Total Publications

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
Journal: Circulation
Published: September 05, 2025
Similar Doctors
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Lori M. Tam
Cardiology
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Lori M. Tam
Cardiology
9427 Southwest Barnes Road, Suite 495, 
Portland, OR 
 (4.0 miles away)
503-962-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lori Tam is a Cardiologist in Portland, Oregon. Dr. Tam is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Spontaneous Coronary Artery Dissection (SCAD), Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure, Pulmonary Edema, and Pacemaker Implantation. Dr. Tam is currently accepting new patients.

Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Brendan J. Daly
Cardiology
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Brendan J. Daly
Cardiology

Legacy Clinics LLC

1040 Nw 22nd Ave, Suite 660, 
Portland, OR 
 (2.1 miles away)
503-413-7162
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brendan Daly is a Cardiologist in Portland, Oregon. Dr. Daly is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure, Pulmonary Edema, Heart Failure with Preserved Ejection Fraction (HFpEF), Atrial Fibrillation, and Pacemaker Implantation. Dr. Daly is currently accepting new patients.

Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Joshua F. Grant
Cardiology | Advanced Heart Failure and Transplant Cardiology
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Joshua F. Grant
Cardiology | Advanced Heart Failure and Transplant Cardiology

Peacehealth

200 Ne Mother Joseph Pl, Suite 400, 
Vancouver, WA 
 (10.0 miles away)
360-256-2640
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joshua Grant is a Cardiologist and an Advanced Heart Failure and Transplant Cardiologist in Vancouver, Washington. Dr. Grant is rated as an Advanced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Pulmonary Veno-Occlusive Disease, Heart Failure, and Pulmonary Edema. Dr. Grant is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heitner's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile